STOCK TITAN

Affimed N.V. - AFMD STOCK NEWS

Welcome to our dedicated news page for Affimed N.V. (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed N.V..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Affimed N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Affimed N.V.'s position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
conferences earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.04%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.78%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.42%
Tags
none
-
-
Affimed N.V.

Nasdaq:AFMD

AFMD Rankings

AFMD Stock Data

87.56M
13.50M
6.01%
35.86%
1.29%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Mannheim

About AFMD

affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli